Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Initial Public Offering	Initial Public Offering Common Stock	Initial Public Offering Additional Paid-In Capital	Private Placement	Private Placement Common Stock	Private Placement Additional Paid-In Capital	Redeemable Convertible Preferred Stock	Convertible Preferred Stock Preferred Stock	Series A-1 Redeemable Convertible Preferred Stock	Series A-2 Redeemable Convertible Preferred Stock
Beginning balance, shares at Dec. 31, 2022												0
Beginning balance, amount at Dec. 31, 2022												$ 0
Beginning balance, shares at Dec. 31, 2022		1,091,800											810,700
Beginning balance, amount at Dec. 31, 2022	$ (35,236)	$ 1	$ 11,761		$ (46,999)								$ 1
Issuance of common stock, net of issuance costs, commissions and offering costs, shares							21,262,181
Issuance of common stock, amount						$ 291,028	$ 21	$ 291,007
Exercise of stock options, shares		27,787
Exercise of stock options, amount	34		34
Vesting of restricted stock	103		103
Stock-based compensation	3,327		3,327
Net loss	(98,147)				(98,147)
Reclassification of Series Seed redeemable convertible preferred stock, shares												810,700
Reclassification of Series Seed redeemable convertible preferred stock, amount												$ 9,830
Reclassification of series seed redeemable convertible preferred stock, shares													(810,700)
Reclassification of series seed redeemable convertible preferred stock, amount	(9,830)		(9,829)										$ (1)
Issuance of redeemable convertible preferred stock, shares														14,796,010
Issuance of redeemable convertible preferred stock, amount														$ 208,701
Issuance of redeemable convertible preferred stock upon conversion of convertible notes, shares															3,229,851
Issuance of redeemable convertible preferred stock upon conversion of convertible notes, amount															$ 35,576
Conversion of redeemable convertible preferred stock to common stock on initial public offering												$ (254,107)
Conversion of redeemable convertible preferred stock to common stock on initial public offering, shares												(18,836,561)
Conversion of redeemable convertible preferred stock to common stock on initial public offering	254,107	$ 19	254,088
Conversion of redeemable convertible preferred stock to common stock on initial public offering, Shares		18,836,561
Issuance of restricted stock awards, shares		1,874
Repurchase of restricted stock		(14,652)
Ending balance, shares at Dec. 31, 2023												0
Ending balance, amount at Dec. 31, 2023												$ 0
Ending balance, shares at Dec. 31, 2023		41,205,551											0
Ending balance, amount at Dec. 31, 2023	405,386	$ 41	550,491		(145,146)								$ 0
Exchange of common stock for pre-funded warrants, shares		(1,842,499)
Exchange of common stock for pre-funded warrants, value	$ (25)	$ (2)	(23)
Issuance of common stock, net of issuance costs, commissions and offering costs, shares										6,471,000
Issuance of common stock, amount									$ 102,888	$ 7	$ 102,881
Exercise of stock options, shares	208,452	208,452
Exercise of stock options, amount	$ 1,174		1,174
Vesting of restricted stock	45		45
Stock-based compensation	17,972		17,972
Net loss	(167,502)				(167,502)
Other comprehensive income	291			$ 291
Ending balance, shares at Dec. 31, 2024		46,042,504
Ending balance, amount at Dec. 31, 2024	$ 360,229	$ 46	$ 672,540	$ 291	$ (312,648)

CARGO Therapeutics, Inc. 10-K